Electra Therapeutics
San Francisco
About Electra Therapeutics
Electra Therapeutics focuses on developing therapies that target the Signal Regulatory Protein (SIRP) family of receptors on immune cells. The company's portfolio of SIRP-directed antibodies is designed to address the underlying pathology across a range of diseases by selectively depleting pathological immune cells. The lead product candidate, ELA026, is a monoclonal antibody currently in pivotal clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition. Electra Therapeutics is also advancing a second program, ELA822, for use in immunology and inflammation conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $283.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2025)
- Website: electra-therapeutics.com
- Phone: 1- 888-743-2290
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/electra-therapeutics-29988 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.